Browse the corpus

Aplastic anemia is a rare yet life-threatening hematologic condition marked by bone marrow failure and subsequent pancytopenia. Prompt recognition and intervention are essential, as untreated disease carries a high mortality rate. Fortunately, advances in treatment—such as hematopoietic stem cell transplantation (HSCT) and triple immunosuppressive therapy (IST)—have significantly improved survival outcomes, with rates exceeding 80%. This activity reviews the complex etiologies of aplastic anemia, including idiopathic, inherited, and environmentally induced causes, as well as critical elements of diagnosis to differentiate acquired forms from inherited marrow failure syndromes, such as Fanconi anemia or dyskeratosis congenita. Participants will also explore evidence-based management strategies for aplastic anemia tailored to disease severity, age, and fitness level, including supportive and lower-intensity therapies. The course emphasizes the role of timely referral to hematology, comprehensive diagnostic evaluation, and long-term monitoring for relapse, clonal evolution, and treatment response. This activity for healthcare professionals is designed to enhance the learner's competence in identifying aplastic anemia, performing the recommended evaluation, and implementing an appropriate interprofessional approach when managing this condition to improve both quality of life and survival for patients with aplastic anemia. Objectives: Identify the underlying pathophysiological mechanisms associated with aplastic anemia. Assess the clinical characteristics associated with aplastic anemia. Implement the appropriate management approach for aplastic anemia. Apply interprofessional team strategies to improve care coordination and outcomes in patients with aplastic anemia. Access free multiple choice questions on this topic.

Aplastic anemia is a rare but serious hematologic disorder characterized by the failure of bone marrow to produce enough blood cells, leading to pancytopenia and causing significant morbidity and mortality.[1] This can result in severe complications, including profound fatigue, increased susceptibility to infections, and a heightened risk of hemorrhage. Aplastic anemia is a life-threatening condition that, if untreated, is associated with very high mortality. However, the advent of bone marrow transplant combined with immunosuppressive therapy (IST) has led to survival rates exceeding 80% to 85%.[2][3] Understanding the underlying causes of aplastic anemia and its pathophysiology is crucial for effective diagnosis and management, as this condition can arise from various factors, including autoimmune disorders, exposure to certain chemicals or medications, and viral infections.[4]

The underlying etiologies of aplastic anemia can be broadly classified into acquired or inherited categories (see Table 1: Aplastic Anemia Etiologies).[5][6][4][1] Acquired aplastic anemia is often linked to environmental factors and external agents, while inherited forms may stem from genetic mutations that affect hematopoiesis. The most common etiology, idiopathic, accounts for 65%. Fanconi anemia is the most common hereditary cause, presenting in the late first decade with pancytopenia, organ hypoplasia, and bone defects, including abnormal radii, absent thumbs, and short stature. Seronegative hepatitis is responsible for 5% to 10% of total cases. Telomerase defects are found in 5% to 10% of adult-onset aplastic anemia and help in guiding clinical decisions.[7] Table Table 1: Aplastic Anemia Etiologies .

Aplastic anemia is a rare disorder with a bimodal age distribution. Research indicates that the incidence ranges from 0.6 to 6.1 cases for every million individuals; this rate is primarily derived from analyses of historical death registries. The ratio of males to females is roughly 1:1. Younger age, male predominance, and higher consanguinity suggest that genetic factors may play a role in the etiology of aplastic anemia among the South Asian population.[1] The prevalence of adult aplastic anemia in Thailand and Taiwan exceeds that found in Western nations, with a particularly high incidence among older individuals.[8][9] Aplastic anemia can affect individuals across all age groups, but the initial peak in incidence occurs within the first 30 years, followed by a secondary peak in older patients (those older than 60).[10] Patients with severe forms of the disease experience lower 5-year survival rates.[11] An increased incidence of aplastic anemia has been associated with the inheritance of certain human leukocyte antigen (HLA) class I alleles that vary among populations.[12] A higher prevalence of autoimmune anemia has been associated with the genetic transmission of specific HLA class I alleles that exhibit differences across different populations.[12]

Aplastic anemia is characterized by the failure of hematopoietic stem cells in the bone marrow, leading to pancytopenia. The pathogenesis involves both immune-mediated and intrinsic mechanisms, as well as genetic and environmental factors. This multifactorial pathophysiology highlights the complexity of aplastic anemia and underscores the importance of a targeted therapeutic approach. Immune-Mediated Suppression The following pathophysiological processes are associated with autoimmune responses, resulting in the depletion of hematopoietic stem cells in aplastic anemia: T-cell-mediated cytotoxicity: Autoreactive T-helper lymphocytes (T1) secrete cytokines (eg, IFN-γ and TNF), thus triggering the apoptotic pathway in hematopoietic stem cells. As a result, this observation supports the theory that immunosuppressive treatments targeting T-cells (including antithymocyte globulin) have demonstrated effectiveness for numerous patients.[13][14] HLA class I alleles: Certain HLA class I alleles have been identified as either elevated or reduced in cases of aplastic anemia, suggesting that CD8+ T cells might be targeting the bone marrow as a result of immune reactions similar to those seen in viral infections or autoimmune responses.[15][12][16][17] Hepatitis-associated aplastic anemia (HAAA): In cases of HAAA, severe autoimmune hepatitis typically presents before aplastic anemia, frequently arising within a 6-month timeframe.[13] HAAA exhibits a distinct immune signature marked by oligoclonality and a diminished count of CD4+ T cells compared to idiopathic aplastic anemia.[18] Cytokine dysregulation: Pro-inflammatory cytokines, eg, IFN-γ and TNF-α, exert an inhibitory effect on hematopoiesis without inducing direct harm to hematopoietic stem cells.[19] Myeloid dendritic cell: The levels of mDC1 are higher in cases of severe aplastic anemia and are associated with the intensity of the disease. This indicates that mDC1 could play a crucial role and serve as a potential therapeutic target in SAA.[20] Intrinsic Stem Cell Defects Stem cell abnormalities Stem cell abnormalities contribute to bone marrow insufficiency by impairing the function of hematopoietic stem cells, which lose their ability to replicate or mature effectively. This failure in normal hematopoiesis can lead to the development of severe hematologic conditions, including myelodysplastic syndrome.[13] Telomere impairment

Stem cell abnormalities contribute to bone marrow insufficiency by impairing the function of hematopoietic stem cells, which lose their ability to replicate or mature effectively. This failure in normal hematopoiesis can lead to the development of severe hematologic conditions, including myelodysplastic syndrome.[13] Telomere impairment Telomere impairment also plays a crucial role in the depletion of hematopoietic stem cells. Shortened telomeres impact stem cell longevity and function, thereby affecting the effectiveness of various treatment strategies. A clear understanding of telomere dynamics informs clinical decision-making and contributes to improved survival outcomes in patients undergoing stem cell transplantation.[7][21] External Triggers Several external factors can contribute to the development of aplastic anemia. Exposure to specific medications, toxic chemicals, and ionizing radiation can directly damage hematopoietic stem cells, impairing their ability to produce adequate blood cells.[22][23] Agents, eg, chemotherapy drugs, benzene, and other industrial solvents have been associated with this form of marrow suppression. Infectious agents also play a significant role in triggering aplastic anemia. Certain viral infections, including Epstein-Barr virus (EBV), can activate cytotoxic T-cells, which may lead to immune-mediated destruction of bone marrow precursors.[24][25] Additionally, COVID-19 has emerged as a contributing factor, with reports linking the virus to cases of aplastic anemia through similar immune dysregulation mechanisms. Clonal Evolution Aplastic anemia may progress to paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndromes (MDS), or acute myeloid leukemia (AML) due to genetic alterations and chromosomal irregularities.[26][27][28][29][30] Genetic and Environmental Factors Specific genetic variations may predispose certain individuals to heightened susceptibility to hematopoietic stem cell depletion, thereby increasing the probability of developing aplastic anemia.[12]

Clinical Evaluation Patients with aplastic anemia typically present with symptoms of pancytopenia, including fatigue and dyspnea (anemia), infections and fever (neutropenia), and mucosal bleeding or petechiae (thrombocytopenia). Infections are often bacterial; severe neutropenia increases the risk of invasive fungal infections. Some cases are asymptomatic and are detected via abnormal laboratory blood counts, including complete blood count (CBC), reticulocyte count, bone marrow biopsy, and testing for inherited marrow failure syndromes. The urgency of therapeutic intervention depends on the severity of cytopenia and the patient's clinical condition; hence, it requires immediate consultation with both a hospitalist and a hematologist/oncologist, and may necessitate inpatient care.[31][32] Clinical History A thorough history and physical examination are essential in assessing the patient's overall health and identifying potential causes of aplastic anemia. A detailed review of the medical history, including any previous exposure to toxic substances or medications, family history of blood disorders, and current symptom presentation, is vital in guiding further diagnostic tests and treatment plans. Key historical points that should be assessed include: Recent exposure to drugs, toxins, or radiation Recent viral illnesses (eg, hepatitis, EBV, parvovirus B19, COVID-19) Family history of inherited marrow failure syndromes Cytopenia-related symptoms: infections, bleeding, fatigue Physical Examination The physical examination may reveal clinical signs, including pallor, jaundice, or bleeding, which can be crucial in evaluating the severity of the condition and determining the need for prompt medical attention. Other findings associated with aplastic anemia include: Signs of pancytopenia Anemia: Pallor, tachycardia, dyspnea Neutropenia: Fever, signs of infection Thrombocytopenia: Petechiae, bruising, mucosal bleeding Absence of liver, spleen, and lymph node enlargement; notable enlargement of these structures may suggest another diagnosis Inherited aplastic anemia syndromes (eg, Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Schwachman-Diamond syndrome), including short stature, abnormal thumbs, cardiac defects, abnormal skin pigmentation, nail dystrophy, and other congenital abnormalities [33]

Diagnostic Evaluation Laboratory evaluations and a bone marrow biopsy are crucial for confirming the diagnosis and evaluating the severity of cytopenia, which consists of a CBC, reticulocyte count, and peripheral blood smear.[33][34] These diagnostic methods enable the distinction between the various causes of cytopenia and aid in developing suitable treatment strategies based on the identified underlying condition. The following findings on diagnostic studies help in excluding differential diagnoses or identifying aplastic anemia: Peripheral blood findings CBC with differential: Shows pancytopenia Reticulocyte count: Low Telomere length/chromosome breakage test: Rule out inherited marrow failure syndromes Flow cytometry: Aids in evaluating for MDS, leukemia, or PNH by identifying and distinguishing hypoplastic MDS from aplastic anemia.[35] Bone marrow Biopsy: Hypocellular marrow with fatty replacement (see Image. Aplastic Anemia Bone Marrow) No fibrosis or malignant infiltration Aspirate: Often results in a “dry tap” Cytogenetics (karyotype): Typically normal.[36][37] FISH/SNP arrays: Helpful when the aspirate provides a limited number of cells.[37] Next generation sequencing (NGS) panel: Could uncover mutations (eg, DNMT3A, ASXL1) [38][39] Diagnostic Criteria for Aplasitc Anemia Diagnosis of aplastic anemia typically requires a combination of clinical findings, laboratory tests, and the exclusion of other hematological disorders.[33][40] Aplastic anemia is a clinical-pathologic diagnosis that requires both of the following: Bone marrow hypoplasia/aplasia without an infiltrative process The presence of ≥2 of the following cytopenia findings: Reticulocytes <40,000/µL (or <1%) ANC <500/µL Platelets <20,000/µL Severity Grading Aplastic anemia can be categorized according to the severity of bone marrow insufficiency and the presence of peripheral blood cytopenia, thereby guiding clinical management strategies and prognostic assessments (Table 2: Severity Grading).[40] Table Table 2: Severity Grading.

Management of Aplastic Anemia in Adults The treatment of aplastic anemia is highly dependent on the severity of the condition. A comprehensive pretreatment evaluation is crucial to determine the most effective and personalized treatment strategy for individuals affected by this complex and potentially life-threatening condition. Management of aplastic anemia focuses on addressing the underlying cause, emphasizing the importance of an accurate diagnosis and characterization of the anemia. If the underlying cause is identified as exposure to a drug or cytotoxic chemical, discontinuation of the offending agent is recommended, if possible. Aplastic anemia associated with pregnancy is typically self-limiting and resolves with delivery, but relapses are common.[41] In cases involving thymoma, patients often experience full recovery of bone marrow function following thymectomy.[42][43][44] Pretreatment evaluation In cases where no reversible etiology is identified, the therapeutic approach is contingent upon factors, eg, the patient's age, disease severity, donor availability, and the patient's overall functional status. The initial evaluation of aplastic anemia must exclude other causes of pancytopenia, as significant differences in treatment approaches exist. This includes a thorough history, physical examination, laboratory tests, bone marrow examination, cytogenetics, and molecular studies. Exclusion of differential diagnoses Inherited bone marrow failure syndromes (IBMFS) should be considered, particularly in patients younger than 40 years of age.[45] Chromosomal breakage analysis and telomere length analysis are recommended for these patients to identify any underlying genetic abnormalities that may influence treatment decisions and prognosis. Additionally, NGS panels should be obtained to evaluate for genetic mutations causing bone marrow failure, as this impacts factors related to hematopoietic stem cell transplantation (HSCT). Severe Aplastic Anemia and Very Severe Aplastic Anemia Patients with severe aplastic anemia (SAA) or very severe aplastic anemia (vSAA) require prompt treatment to reduce the risk of life-threatening infections and limit complications from ongoing transfusions and medications. A short-term delay in initiating therapy is acceptable for treating serious bacterial infections or sepsis, but not for fungal infections unless they can be managed through surgical means.

Patients with severe aplastic anemia (SAA) or very severe aplastic anemia (vSAA) require prompt treatment to reduce the risk of life-threatening infections and limit complications from ongoing transfusions and medications. A short-term delay in initiating therapy is acceptable for treating serious bacterial infections or sepsis, but not for fungal infections unless they can be managed through surgical means. Medically fit patients For patients aged 40 or younger who are diagnosed with severe aplastic anemia (SAA) or very severe aplastic anemia (vSAA) and possess a rapidly accessible matched related donor (MRD), the utilization of allogeneic HSCT is favored in comparison to immunosuppressive therapy (IST).[46][47][48][49][50][51] In instances where an MRD is not available, the initiation of IST is warranted. For patients older than 40, triple IST (horse antithymocyte globulin [hATG], cyclosporine, and eltrombopag) is advocated due to its superior clinical outcomes compared to IST without eltrombopag.[52][53][54][55][56][57][58] Recent investigations indicate that the incorporation of Avatrombopag (AVA) into IST enhances both the response rate and the quality of response in patients diagnosed with SAA, whilst maintaining a favorable safety profile.[59] Medically unfit or frail patients For individuals who are not deemed suitable candidates for intensive IST or HSCT, therapeutic interventions are tailored to alleviate symptoms and enhance overall quality of life while minimizing the occurrence of adverse effects. IST should be regarded as the primary treatment modality for the majority of older patients diagnosed with SAA.[60] Moderate Aplastic Anemia Indications for the need for therapeutic intervention for moderate aplastic anemia (MAA) are primarily determined by the dependence on red blood cell (RBC) transfusions, which serves as the most frequent reason for initiating treatment, usually becoming apparent after administering 6 to 10 units of RBCs or when the patient's quality of life is significantly affected due to cytopenias. In addition, the ongoing presence of severe neutropenia or thrombocytopenia may also necessitate medical intervention.

Indications for the need for therapeutic intervention for moderate aplastic anemia (MAA) are primarily determined by the dependence on red blood cell (RBC) transfusions, which serves as the most frequent reason for initiating treatment, usually becoming apparent after administering 6 to 10 units of RBCs or when the patient's quality of life is significantly affected due to cytopenias. In addition, the ongoing presence of severe neutropenia or thrombocytopenia may also necessitate medical intervention. For patients considered medically stable, the initial treatment strategy may include lower-intensity IST or monotherapy with eltrombopag. Intensive immunosuppressive therapy is considered suitable for specific individuals, while HSCT is rarely viewed as a first-line option but may be chosen by younger patients facing significant transfusion needs or who have coexisting infections. In vulnerable patients, supportive care is prioritized, focusing on symptom relief and improving quality of life. Treatment Approach for Severe Aplastic Anemia Various management strategies may be used in patients with SAA, including pharmacologic treatment, supportive therapies, and surveillance. Hematopoietic stem cell transplantation (HSCT) Allogeneic HSCT can induce remission in aplastic anemia. HSCT fulfills the dual role of restoring the pool of hematopoietic stem/progenitor cells while simultaneously replacing the immune system, which is involved in their loss. The absolute neutrophil count before allogeneic HSCT has been recognized as a crucial prognostic factor in adult populations diagnosed with aplastic anemia.[61] Triple immunosuppressive therapy (IST) Horse antithymocyte globulin (hATG) functions by eliminating antigen-specific T lymphocytes and facilitating hematologic responses in cases of aplastic anemia. Cyclosporine inhibits the synthesis and secretion of interleukin-2 (IL-2) while concurrently blocking the IL-2-mediated activation of quiescent T lymphocytes. Eltrombopag, classified as a non-peptide agonist of thrombopoietin, augments platelet counts and stimulates intracellular signal transduction pathways that promote the proliferation and differentiation of hematopoietic progenitor cells within the marrow.[54] The implementation of triple IST is favored over the combination of hATG and cyclosporine alone due to the superior clinical outcomes observed.[53][54][62]

Horse antithymocyte globulin (hATG) functions by eliminating antigen-specific T lymphocytes and facilitating hematologic responses in cases of aplastic anemia. Cyclosporine inhibits the synthesis and secretion of interleukin-2 (IL-2) while concurrently blocking the IL-2-mediated activation of quiescent T lymphocytes. Eltrombopag, classified as a non-peptide agonist of thrombopoietin, augments platelet counts and stimulates intracellular signal transduction pathways that promote the proliferation and differentiation of hematopoietic progenitor cells within the marrow.[54] The implementation of triple IST is favored over the combination of hATG and cyclosporine alone due to the superior clinical outcomes observed.[53][54][62] Lower-intensity aplastic anemia treatments Eltrombopag is a non-peptide thrombopoietin receptor (TPO-R) agonists that serve to enhance the proliferation of hematopoietic and megakaryocyte progenitor cells.[63] Administering this medication either in a fasted state or concurrently with a meal that is low in calcium content is recommended. Reduced-intensity immunosuppressive therapy (IST), which involves the use of cyclosporine A either alone or in combination with alternative immunosuppressive agents, has yielded suboptimal therapeutic outcomes when compared to the standard regimen of horse antithymocyte globulin (hATG) combined with cyclosporine. In patients with SAA who present with compromised cardiac or renal function, the preferred clinical approach focuses on optimizing underlying medical conditions to enable the use of full triple IST, rather than defaulting to a lower-intensity regimen. Cyclosporine monotherapy in MAA has demonstrated a response rate of 46%, a transfusion-independence rate of 67%, and an overall survival rate of 93% at 180 days. The combination of cyclosporine and eltrombopag, excluding hATG, remains under investigation for older or medically frail patients diagnosed with MAA. Cyclosporine used in conjunction with levamisole has achieved a 100% response rate in newly diagnosed MAA cases and an 87% response rate in chronic MAA cases.[33] Monitoring

Cyclosporine monotherapy in MAA has demonstrated a response rate of 46%, a transfusion-independence rate of 67%, and an overall survival rate of 93% at 180 days. The combination of cyclosporine and eltrombopag, excluding hATG, remains under investigation for older or medically frail patients diagnosed with MAA. Cyclosporine used in conjunction with levamisole has achieved a 100% response rate in newly diagnosed MAA cases and an 87% response rate in chronic MAA cases.[33] Monitoring Patients administered hATG are susceptible to experiencing infusion reactions and serum sickness. Monitoring for these adverse effects is crucial, and premedication with antihistamines or corticosteroids might be warranted to alleviate reactions throughout the therapeutic regimen.[64][65][66] Consistent evaluation of hematological parameters, renal function, and trough concentrations of cyclosporine is essential. Clinicians should monitor for secondary hemochromatosis and administer iron chelation therapy when clinically necessary. The use of growth factors, eg, erythropoietin or granulocyte colony-stimulating factors, is not recommended due to a lack of precursor cells required to achieve sufficient physiological responses. Supportive therapy Transfusion support plays a crucial role in managing patients with severe anemia or thrombocytopenia resulting from aplastic anemia. RBC transfusions help alleviate symptoms such as fatigue and dyspnea, while platelet transfusions reduce the risk of spontaneous bleeding and help maintain hemostasis. These interventions contribute significantly to improving quality of life and overall clinical stability. Preventing infections remains a top priority, as infections represent the most common cause of mortality in individuals with aplastic anemia. The development of fever in the context of an absolute neutrophil count below 500/µL constitutes a medical emergency requiring urgent evaluation and intervention. Prophylactic measures against Pneumocystis jirovecii should include agents such as sulfamethoxazole/trimethoprim or pentamidine. Antifungal and antiviral prophylaxis should also be tailored to the patient's specific risk profile to reduce the likelihood of life-threatening infections.[67] Follow-up and treatment responses

Preventing infections remains a top priority, as infections represent the most common cause of mortality in individuals with aplastic anemia. The development of fever in the context of an absolute neutrophil count below 500/µL constitutes a medical emergency requiring urgent evaluation and intervention. Prophylactic measures against Pneumocystis jirovecii should include agents such as sulfamethoxazole/trimethoprim or pentamidine. Antifungal and antiviral prophylaxis should also be tailored to the patient's specific risk profile to reduce the likelihood of life-threatening infections.[67] Follow-up and treatment responses Patients undergoing IST for aplastic anemia require consistent monitoring to assess treatment response, detect toxicities, and identify signs of clonal progression. During the first 6 months of treatment, outpatient visits occur every 2 to 4 weeks. Biweekly evaluations include CBC, reticulocyte counts, liver transaminases, and cyclosporine A levels. Bone marrow examinations are conducted at the 3-month and 6-month marks, especially for patients showing partial responses, to evaluate marrow cellularity and treatment effectiveness. After the initial 6-month period, monitoring continues for patients who maintain stability on eltrombopag and/or cyclosporine A. Once therapy is discontinued, follow-up visits are scheduled every 3 to 6 months, gradually extending to annual evaluations after 2 to 3 years, depending on the patient's clinical course. Assessment of hematologic response involves several benchmarks. Transfusion independence and improved peripheral blood counts indicate a favorable outcome. A complete response includes transfusion independence, hemoglobin levels above 10 g/dL, and platelet counts exceeding 50,000/µL. A partial response indicates improved blood counts or decreased transfusion requirements, but does not meet the full response criteria. Refractory disease shows minimal or no improvement despite therapy, while relapse is defined by a subsequent decline in blood counts after an initial hematologic response. Refractory Aplastic Anemia Refractory aplastic anemia is a challenging condition that often requires alternative therapeutic strategies, including the consideration of IST or HSCT for eligible patients.

Assessment of hematologic response involves several benchmarks. Transfusion independence and improved peripheral blood counts indicate a favorable outcome. A complete response includes transfusion independence, hemoglobin levels above 10 g/dL, and platelet counts exceeding 50,000/µL. A partial response indicates improved blood counts or decreased transfusion requirements, but does not meet the full response criteria. Refractory disease shows minimal or no improvement despite therapy, while relapse is defined by a subsequent decline in blood counts after an initial hematologic response. Refractory Aplastic Anemia Refractory aplastic anemia is a challenging condition that often requires alternative therapeutic strategies, including the consideration of IST or HSCT for eligible patients. HSCT is the preferred method for eligible patients, particularly when a matched related donor is available. For patients who do not qualify for HCT, options include Eltrombopag or hATG-based treatments.[68] Relapsing Aplastic Anemia Relapse occurs in up to one-third of patients with SAA. Management is guided by serial blood counts and bone marrow exams. A second course of IST can be effective in 55% to 60% of patients, but salvage HSCT may be a more preferable treatment option for relapses or refractory cases.

The differential diagnosis of pancytopenia encompasses several conditions that may resemble aplastic anemia. Myelophthisic syndrome, characterized by the replacement of normal bone marrow by tumors or fibrosis, is caused by solid tumor metastases (eg, lung, breast, prostate), myeloid or lymphoid malignancies, or disorders like Gaucher disease. Unlike aplastic anemia, these conditions typically present with marrow that is not hypocellular, reflecting the underlying disease. Isolated hematopoietic lineage failure, eg, agranulocytosis or pure red cell aplasia, shares etiologies with aplastic anemia but presents with symptoms specific to the affected cell line. Reversible marrow suppression, caused by chemotherapy, radiation, sepsis, or viral infections, can mimic aplastic anemia but is distinguished by the transient nature of blood count abnormalities and the absence of hypocellularity on bone marrow biopsy.[32] Additionally, megaloblastic anemia, hypersplenism, malignancies, myelofibrosis, infections, and inherited bone marrow failure syndromes (eg, Fanconi anemia, Shwachman-Diamond syndrome) must be considered.[69] These conditions have distinguishing features, including hypersegmented neutrophils and macroovalocytes in megaloblastic anemia, or splenomegaly in hypersplenism.[70][20]

Over the past 3 decades, the prognosis for patients with aplastic anemia has improved significantly due to advances in IST and HSCT, with a 10-year survival rate increased, especially for sibling-matched HCT.[71][72] However, IST carries risks of relapse and late clonal evolution, with leukocyte telomere length linked to poor survival and increased relapse.[7][73] In severe aplastic anemia (SAA), survival rates range from 80% to 90%, with younger patients and those with higher reticulocyte and lymphocyte counts experiencing better outcomes.[74] The presence of preexisting anti-HLA antibodies negatively affects platelet recovery and overall prognosis in SAA patients undergoing allogeneic HCT.[75] Despite the benefits of HSCT, complications, eg, graft-versus-host disease and graft failure, remain significant risks.[76] Factors like higher ECOG scores and infections are associated with poorer posttransplant outcomes.[76] Delayed HLA-PB haplo-HSCT for severe aplastic anemia yielded poor outcomes. Rapid referral for HSCT is critically required.[77] Haplo-HSCT should be considered an effective alternative for patients with SAA without a matched sibling donor.[78]

The most common complications of aplastic anemia include bleeding, infections, or transformation to lymphoproliferative disorders. These conditions are managed through surveillance and symptomatic treatment, which may include antibiotics, chemotherapy, and transfusions.

Deterrence in aplastic anemia primarily involves minimizing exposure to known risk factors and addressing modifiable contributors to bone marrow failure. Patients should receive guidance on avoiding toxic chemicals, eg, benzene, certain pesticides, and medications known to affect hematopoiesis. Individuals with a family history of inherited marrow failure syndromes may benefit from genetic counseling to assess potential risks and guide early screening. Prompt evaluation and management of viral infections, including hepatitis viruses and Epstein-Barr virus, can also reduce the likelihood of immune-mediated marrow suppression. In cases involving drug-induced aplastic anemia, immediate discontinuation of the offending agent is essential to prevent progression. Patient education plays a crucial role in enhancing outcomes and fostering self-management. Clinicians should inform patients about the signs and symptoms of cytopenia, eg, fatigue, infections, and bleeding, and emphasize the importance of routine follow-up visits, laboratory monitoring, and adherence to medication. Education on infection prevention strategies, including hand hygiene, avoidance of crowded places during periods of neutropenia, and prompt reporting of fever, remains crucial. Patients should also understand the rationale behind treatment choices, including immunosuppressive therapy, hematopoietic stem cell transplantation, and supportive care, so they can actively participate in shared decision-making and recognize the need for urgent care in cases of relapse or complications.

Pancytopenia, defined as the simultaneous reduction of erythrocytes, leukocytes, and platelets, is a hematologic finding with a broad differential diagnosis that includes bone marrow failure syndromes, infiltrative diseases, nutritional deficiencies, and hematologic malignancies. Aplastic anemia represents a distinct etiology of pancytopenia, characterized by immune-mediated destruction or suppression of hematopoietic stem cells, resulting in a markedly hypocellular bone marrow without malignant infiltration or fibrosis. This condition must be differentiated from other causes of pancytopenia, eg, myelophthisic syndrome, which results from the pathological replacement of normal hematopoietic marrow with abnormal tissue. Etiologies of myelophthisic syndrome include metastatic solid tumors (eg, breast, lung, or prostate cancer), hematologic malignancies (eg, acute myeloid leukemia), myelofibrosis, hemophagocytic lymphohistiocytosis, osteopetrosis, and lysosomal storage disorders such as Gaucher disease. In these cases, bone marrow biopsy typically reveals preserved or increased cellularity with evidence of infiltrative or fibrotic processes, rather than the hypocellularity observed in aplastic anemia. Additionally, isolated failure of a single hematopoietic lineage may occur, manifesting as agranulocytosis or pure red cell aplasia, and may share etiologic factors with aplastic anemia, including drug exposures (eg, propylthiouracil) and paraneoplastic syndromes (eg, thymoma-associated red cell aplasia). Unlike aplastic anemia, these conditions are associated with cytopenia limited to a specific cell line, and clinical manifestations correspond to the deficient lineage rather than global bone marrow suppression. Accurate diagnosis relies on a comprehensive evaluation including peripheral blood counts, bone marrow biopsy, and assessment for underlying systemic or malignant processes, as treatment strategies vary significantly depending on the etiology.

The successful management of aplastic anemia relies on a highly coordinated interprofessional approach that emphasizes patient-centered care, clinical vigilance, and evidence-based decision-making. Physicians and advanced practitioners, including hematologists and transplant specialists, lead diagnostic and therapeutic planning by assessing disease severity and determining the appropriateness of immunosuppressive therapy or hematopoietic stem cell transplantation. Close collaboration with infectious disease consultants ensures early identification and treatment of infections, particularly in the setting of profound neutropenia. Nurses play a central role in daily patient care, administering medications, educating patients and families, and monitoring for signs of bleeding, infection, or drug toxicity. Pharmacists contribute by reviewing complex treatment regimens, adjusting dosages based on renal or hepatic function, and ensuring safe administration of immunosuppressants and prophylactic antimicrobials. Coordination with hospitalists ensures seamless transitions across care settings, while dietitians provide tailored nutritional counseling, especially for patients following neutropenic dietary precautions. Effective interprofessional communication and structured care pathways remain vital for enhancing safety and optimizing outcomes. Regular case conferences and handoffs among team members promote early recognition of complications and reinforce shared decision-making that aligns with patient goals. Nurses and advanced practitioners serve as essential patient advocates, reinforcing education on infection prevention, dietary restrictions, and activity limitations to prevent trauma-related hemorrhage. Nutritional counseling plays a critical role; neutropenic dietary precautions should be implemented, with avoidance of high-risk foods such as unpasteurized dairy products, raw or undercooked meats, and unwashed fruits and vegetables, which may harbor pathogenic microorganisms. Hormonal therapy may be discussed by specialists in collaboration with gynecologists for the management of menorrhagia in premenopausal women.

Effective interprofessional communication and structured care pathways remain vital for enhancing safety and optimizing outcomes. Regular case conferences and handoffs among team members promote early recognition of complications and reinforce shared decision-making that aligns with patient goals. Nurses and advanced practitioners serve as essential patient advocates, reinforcing education on infection prevention, dietary restrictions, and activity limitations to prevent trauma-related hemorrhage. Nutritional counseling plays a critical role; neutropenic dietary precautions should be implemented, with avoidance of high-risk foods such as unpasteurized dairy products, raw or undercooked meats, and unwashed fruits and vegetables, which may harbor pathogenic microorganisms. Hormonal therapy may be discussed by specialists in collaboration with gynecologists for the management of menorrhagia in premenopausal women. Comprehensive discharge planning and outpatient follow-up require consistent communication across disciplines to ensure continuity of care, medication adherence, and long-term monitoring. Through deliberate teamwork and clear role delineation, the interprofessional team enhances treatment success, minimizes risks, and supports patients as they navigate the complexities of aplastic anemia care.[71][72]